In this post we ask what about the patient when healthcare providers plan treatment changes to save money. Is too much emphasis placed on the cost of care?
So today is a big day for me. After 11 months of fighting the reversal of the decision to switch me from Humira to the cheaper Biosimilar Imraldi, which subsequently resulted in one of the biggest flares I’ve had in recent years, the switch back to Humira is finally here! […]
Some people have asked me for links to or further reading on the original decision and announcement by the NHS to move to biosimilars at the end of biologics patents in 2018. Below are a couple of high level ones that came out at the time of the announcement. Note […]